Outcomes for relapsed follicular lymphoma
| Therapy . | Target . | N . | CR, % . | ORR, % . | mDOR, mo . | mPFS, mo . |
|---|---|---|---|---|---|---|
| Rituximab32 | CD20 | 70 | 16 | 56 | 12 | — |
| Obinutuzumab + BR26 | CD20 + chemo | 164 | 16 | 79 | NR | 25.3 |
| 90Y ibritumomab tiuxetan25 | CD20/RIT | 73 | 30 | 80 | 14.2 | — |
| Idelalisib27 | PI3Kδ | 72 | 6 | 57 | 12.5 | 11 |
| Copanlisib28 | PI3Kαδ | 102 | 14 | 59 | 13 | 11.2 |
| Lenalidomide + rituximab30 | IMID/CD20 | 128 | 30 | 66 | NR | 1 y, 70% |
| Ibrutinib33 | BTK | 40 | 12.5 | 37.5 | 13.9 | 14 |
| Tazemetostat31 | EZH2 | 67 | 6 | 39 | — | — |
| CAR T34 | CD19 | 14 | 71 | 79 | — | NR |
| Therapy . | Target . | N . | CR, % . | ORR, % . | mDOR, mo . | mPFS, mo . |
|---|---|---|---|---|---|---|
| Rituximab32 | CD20 | 70 | 16 | 56 | 12 | — |
| Obinutuzumab + BR26 | CD20 + chemo | 164 | 16 | 79 | NR | 25.3 |
| 90Y ibritumomab tiuxetan25 | CD20/RIT | 73 | 30 | 80 | 14.2 | — |
| Idelalisib27 | PI3Kδ | 72 | 6 | 57 | 12.5 | 11 |
| Copanlisib28 | PI3Kαδ | 102 | 14 | 59 | 13 | 11.2 |
| Lenalidomide + rituximab30 | IMID/CD20 | 128 | 30 | 66 | NR | 1 y, 70% |
| Ibrutinib33 | BTK | 40 | 12.5 | 37.5 | 13.9 | 14 |
| Tazemetostat31 | EZH2 | 67 | 6 | 39 | — | — |
| CAR T34 | CD19 | 14 | 71 | 79 | — | NR |
—, data unavailable; BR, bendamustine and rituximab; BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; chemo, chemotherapy; CR, complete response; EZH2, enhancer of zeste homolog 2; IMID, immunomodulatory drug; mDOR, median duration of response; mPFS, median progression-free survival; NR, not reached; ORR, overall response rate; PI3K, phosphatidylinositol 3-kinase; RIT, radioimmunotherapy.